Psoriatic Immune Response to Tildrakizumab

Description

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.

Conditions

Psoriasis Vulgaris

Talk to us

Study Overview

On this page

Study Details

Study overview

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.

Psoriatic Immune Response to Tildrakizumab

Psoriatic Immune Response to Tildrakizumab

Condition
Psoriasis Vulgaris
Intervention / Treatment

-

Contacts and Locations

San Francisco

University of California, San Francisco, San Francisco, California, United States, 94115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 18 years of age or older
  • * Patients with moderate-severe psoriasis or \> 5% body surface area affected.
  • * taking systemic immunosuppressives in the last 4 weeks
  • * pregnancy
  • * severe immunodeficiency (either from genetic or infectious causes).
  • * tuberculosis or other active serious infection
  • * active systemic malignancy.
  • * breast-feeding
  • * Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, San Francisco,

Raymond Cho, MD, PhD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

2025-09-01